Primaquine: Difference between revisions
(Replace manual dosing with dynamic SMW tables (Adult + Pediatric)) |
(Restore original dosing content alongside dynamic SMW tables) |
||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*[[PCP pneumonia]], HIV+ : 15-30mg PO daily with clindamycin | |||
*[[Malaria]] treatment: 26.3-52.6mg PO daily in combination with an additional anti-malarial agent | |||
*[[Malaria]] prophylaxis: 52.6mg PO daily starting 1-2 days prior to arrival in endemic area until 7-14 days after departure | |||
===Indications by Disease=== | ===Indications by Disease=== | ||
{{#ask: [[Has DrugName::Primaquine]] [[Has Population::Adult]] | {{#ask: [[Has DrugName::Primaquine]] [[Has Population::Adult]] | ||
|?Treats disease=Disease | |?Treats disease=Disease | ||
|?Has Dose=Dose | |?Has Dose=Dose | ||
|?Has Context=Context | |?Has Context=Context | ||
|format=table | |format=table | ||
|limit=50 | |limit=50 | ||
|mainlabel=- | |mainlabel=- | ||
|headers=show | |headers=show | ||
|sort=Treats disease | |sort=Treats disease | ||
}} | }} | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*[[Malaria]] treatment: 0.8 mg/kg PO daily (max 52.6mg daily) in combination with an additional anti-malarial agent | |||
*[[Malaria]] prophylaxis: 0.8 mg/kg PO daily (max 52.6mg daily) starting 1-2 days prior to arrival in endemic area until 7-14 days after departure | |||
===Indications by Disease=== | ===Indications by Disease=== | ||
{{#ask: [[Has DrugName::Primaquine]] [[Has Population::Pediatric]] | {{#ask: [[Has DrugName::Primaquine]] [[Has Population::Pediatric]] | ||
|?Treats disease=Disease | |?Treats disease=Disease | ||
|?Has Dose=Dose | |?Has Dose=Dose | ||
|?Has Context=Context | |?Has Context=Context | ||
|format=table | |format=table | ||
|limit=50 | |limit=50 | ||
|mainlabel=- | |mainlabel=- | ||
|headers=show | |headers=show | ||
|sort=Treats disease | |sort=Treats disease | ||
}} | }} | ||
Latest revision as of 02:39, 20 March 2026
Administration
- Type: Antimalarial, anti-PCP
- Dosage Forms:
- Routes of Administration: oral
- Common Trade Names:
Adult Dosing
- PCP pneumonia, HIV+ : 15-30mg PO daily with clindamycin
- Malaria treatment: 26.3-52.6mg PO daily in combination with an additional anti-malarial agent
- Malaria prophylaxis: 52.6mg PO daily starting 1-2 days prior to arrival in endemic area until 7-14 days after departure
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Pneumocystis jirovecii pneumonia | 30mg PO q24hrs | Mild disease with Clindamycin |
| Pneumocystis jirovecii pneumonia | 30mg PO once daily | Severe disease with Clindamycin |
Pediatric Dosing
- Malaria treatment: 0.8 mg/kg PO daily (max 52.6mg daily) in combination with an additional anti-malarial agent
- Malaria prophylaxis: 0.8 mg/kg PO daily (max 52.6mg daily) starting 1-2 days prior to arrival in endemic area until 7-14 days after departure
Indications by Disease
Special Populations
- Pregnancy Rating: D
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing:
- Hepatic dosing:
Contraindications
- Allergy to class/drug
- Concomitant use with other potentially hemolytic or myeloid suppressing drugs
- Acutely ill patients with diseases prone to granulocytopenia (e.g. SLE or rheumatoid arthritis)
Adverse Reactions
Serious
- Hemolytic anemia, leukopenia
- Methemoglobinemia
Common
- Nausea, abdominal pain
Pharmacology
- Half-life: 4-7 hours
- Metabolism:
- Excretion:
Mechanism of Action
- Eliminates tissue infection, thus preventing erythrocytic forms of parasite